Analysts forecast that Mateon Therapeutics Inc (NASDAQ:MATN) will post ($0.11) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Mateon Therapeutics’ earnings. Mateon Therapeutics posted earnings per share of ($0.12) during the same quarter last year, which suggests a positive year-over-year growth rate of 8.3%. The business is expected to report its next earnings results on Monday, November 13th.

On average, analysts expect that Mateon Therapeutics will report full year earnings of ($0.42) per share for the current financial year. For the next year, analysts anticipate that the business will post earnings of ($0.50) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Mateon Therapeutics.

Mateon Therapeutics (NASDAQ:MATN) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.03).

Separately, Maxim Group reissued a “hold” rating on shares of Mateon Therapeutics in a research report on Tuesday, August 1st.

ILLEGAL ACTIVITY NOTICE: “-$0.11 Earnings Per Share Expected for Mateon Therapeutics Inc (MATN) This Quarter” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at

Mateon Therapeutics (NASDAQ MATN) remained flat at $0.26 during mid-day trading on Thursday. The company’s stock had a trading volume of 94,716 shares. Mateon Therapeutics has a 12 month low of $0.16 and a 12 month high of $0.89. The firm has a 50 day moving average price of $0.39 and a 200 day moving average price of $0.48. The company’s market cap is $6.90 million.

Mateon Therapeutics Company Profile

Mateon Therapeutics, Inc, formerly OXiGENE, Inc, is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT.

Get a free copy of the Zacks research report on Mateon Therapeutics (MATN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with's FREE daily email newsletter.